Literature DB >> 10080262

Selegiline augmentation of antipsychotics for the treatment of negative symptoms in schizophrenia.

S Gupta1, T Droney, A Kyser, P Keller.   

Abstract

This case series describes three patients with a DSM-IV diagnosis of schizophrenia attending a continuing day treatment (CDT) program. They showed significant improvement in negative symptoms and overall functioning after the addition of selegiline to the antipsychotic regimen. No side effects were observed with this combination.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10080262     DOI: 10.1016/s0010-440x(99)90119-0

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  2 in total

1.  Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia.

Authors:  Robert W Buchanan; Elaine Weiner; Deanna L Kelly; James M Gold; William R Keller; James A Waltz; Robert P McMahon; David A Gorelick
Journal:  Schizophr Bull       Date:  2014-11-02       Impact factor: 9.306

Review 2.  Potential drug targets and treatment of schizophrenia.

Authors:  Anil Kumar; Monu Yadav; Milind Parle; Sameer Dhingra; Dinesh K Dhull
Journal:  Inflammopharmacology       Date:  2017-03-28       Impact factor: 4.473

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.